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Purpose: To emphasize the effect of photodynamic therapy (PDT) on the size and progression 
of the neovascular lesion (NL) and evolution of the disciform scar (DS) in predominantly classic 
subfoveal choroidal neovascularization (SFCNV).
Methods: A retrospective study of 62 eyes treated with PDT for SFCNV was performed. 
The greatest linear dimension (GLD) before and at last follow-up after treatment and the size 
of the DS post-PDT were analyzed. A subgroup of patients with DS in their fellow eye at 
presentation without prior PDT was also studied. The size of the scar in these eyes was compared 
to that following PDT.
Results: After an average follow-up at 9 months, the size of the NL was stabilized or reduced in 
64% of the study eyes with absence of ﬂ  uorescein leakage in 45%. Only 3 eyes (5%) developed 
DS. At presentation, 14 patients already had DS in their fellow eye, the size of which was 
signiﬁ  cantly larger than that post-PDT (p = 0.044). It was also signiﬁ  cantly larger than that of 
the potential scar in the study eyes of the same subgroup of patients (p = 0.002) and of the rest 
of the patients (p = 0.0001).
Conclusion: This study demonstrates a beneﬁ  cial effect for PDT on the size of the NL and 
DS in SFCNV, which might be of great signiﬁ  cance, particularly when PDT fails to prevent 
severe vision loss.
Keywords: age-related macular degeneration, choroidal neovascularization, classic choroidal 
neovascularization, disciform scarring, ﬂ  uorescein angiography, photodynamic therapy
Introduction
Age-related macular degeneration (AMD) is the leading cause of legal blindness 
in the elderly (Klein et al 1995). The main reason for visual loss in these patients 
is the development of choroidal neovascularization (CNV) in the macular area, 
mainly in the subfoveal region (Ferris et al 1984; MPSG 1993). Subfoveal choroidal 
neovascularization (SFCNV) is also a common cause of vision loss in pathologic 
myopia (Soubrane and Coscas 2001) and the presumed ocular histoplasmosis syndrome 
(POHS) (Olk et al 1984). Since its introduction, PDT has had a great impact on the 
management of SFCNV (Bressler and Bressler 2000; Margherio 2000) and its beneﬁ  t 
in reducing the risk of vision loss has been documented in large multicenter clinical 
trials in the case of AMD (TAP 1999; Bressler 2001, 2002; VIP 2001b) and myopia 
(VIP 2001a). Some evidence for its beneﬁ  t in other causes of SFCNV is also available 
(Sickenberg et al 2000; Saperstein et al 2002; Busquets et al 2003). Although these 
trials included data regarding the ﬂ  uorescein angiographic outcomes and progression 
of the CNV lesion following PDT, the main emphasis was on visual outcome and 
the reduction in the risk of vision loss. However, these studies, and data from other 
studies (Schmidt-Erfurth 1999; Michels et al 2000), suggest that PDT could limit Clinical Ophthalmology 2008:2(4) 774
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progression of and reduce ﬂ  uorescein leakage from CNV 
lesions. Our study exclusively discusses the beneﬁ  cial effect 
of PDT on the progression and size of the CNV lesion, and 
on the evolution of the disciform scar (DS) in patients with 
predominantly classic SFCNV. We also comment on why 
this effect may be desirable even when PDT fails to reduce 
the risk of vision loss.
Methods
Following Institute Review Board approval, we performed 
a retrospective chart review of all patients who received 
verteporﬁ  n-mediated PDT for SFCNV at the Department of 
Ophthalmology at the University of Virginia Health System 
during a 2-year period. All patients were treated by two of us 
(JST and BPC). Patients with AMD and non-AMD-related 
predominantly classic (SFCNV) (area of classic CNV 
occupies 50% or more of the area of the entire lesion) were 
included. All cases that demonstrated ophthalmoscopic and 
ﬂ  uorescein angiographic evidence of “retinal angiomatous 
proliferation” (RAP) (Yannuzzi 2001) were excluded.
To be included in this study, each treated eye had to 
complete at least 6 months of follow-up after the first 
PDT treatment. In addition, the CNV lesion had to meet 
the eligibility criteria set in the TAP and VIP trials (TAP 
1999; VIP 2001a). Also, the treatment, re-treatment and 
follow-up methods had to adhere to the standard protocol of 
verteproﬁ  n-mediated PDT used in these trials. Only two minor 
deviations were allowed. First, eyes with initial best-corrected 
visual acuity worse than 20/200 for AMD and 20/100 for 
myopia were included. Second, only rarely eyes whose follow 
up did not precisely adhere to the TAP (1999) and VIP (2001a) 
follow-up protocol were included. The breach to the protocol 
in such eyes was that ﬂ  uorescein angiography (FA) was not 
necessarily performed on all follow-up visits. These were 
stable eyes that had dramatic and sustained improvement in 
symptoms with visual stabilization following PDT, in which 
the treating physician found no funduscopic evidence of active 
CNV on later follow up visits.
In each case, the etiology of the neovascular lesion, 
the indication for PDT, the number of treatment sessions, 
and the range of follow up were noted. Also, the size of 
the neovascular lesion, estimated by the greatest linear 
dimension (GLD) of the lesion (TAP 1999), was measured 
before treatment and at the last follow up following treatment. 
Then, the percentage change in lesion size; the percentage 
of eyes with stable, reduced, or progressed neovascular 
lesion (according to TAP grading criteria of ﬂ  uorescein 
angiographic assessment at follow up); and the percentage 
of eyes that developed disciform scarring following 
PDT were calculated.
A subgroup of 14 cases that received PDT to one eye 
only (study eye) and already had a DS in the fellow eye at 
presentation was analyzed. None of the latter eyes received 
PDT prior to scar development. The size of the DS, as 
estimated by its GLD, was measured in each case from 
funduscopic and angiographic data. The average size of 
these scars was calculated and compared to that of the DS 
that developed following PDT in some eyes. Also it was 
compared to the average size of the DS that could have 
potentially developed following PDT in the study eyes of 
the same 14 patients, and in the study eyes of the rest of 
the patients. In each of these comparisons, a double-tailed 
student’s t-test was performed to assess signiﬁ  cance.
The size of the DS that could have potentially developed 
in the study eyes over the follow-up period after PDT was 
calculated based on the following. In eyes that had no 
progression or less CNV leakage by TAP criteria (TAP 1999), 
the size of the potential DS was approximated by the size 
of the pre-treatment neovascular lesion. We believe this is 
appropriate because PDT is believed to cause occlusion of the 
vascular component of the neovascular lesion without affecting 
the ﬁ  brous component (Ghazi et al 2001). So although by 
TAP criteria (TAP 1999) the size (GLD) of the entire lesion 
and CNV leakage might angiographically decrease following 
PDT, the neovascular membrane, with its occluded vessels and 
ﬁ  brous matrix, anatomically persists with no regression. In eyes 
with progression following PDT, the size of the potential DS 
was approximated by the size of the post-treatment neovascular 
lesion at the last follow up visit.
Results
One hundred and forty eight eyes of 137 patients were 
treated with verteporﬁ  n-mediated PDT for SFCNV at the 
Department of Ophthalmology at the University of Virginia 
Health System over a period of 2 years. Careful review of the 
charts of these patients disclosed that 62 eyes of 60 patients 
satisﬁ  ed the inclusion criteria of this study. The major reasons 
for exclusion included less than 6 months follow-up after the 
ﬁ  rst PDT session, nonpredominantly classic SFCNV, and/or 
evidence of “RAP” (Yannuzzi et al 2001). The following is a 
report of the results obtained from analysis of the 62 eyes.
Sixty patients received PDT to only one eye and two patients 
had PDT performed to both eyes. Ninety-ﬁ  ve percent (59/62) of 
the eyes had predominantly classic SFCNV secondary to AMD. 
The remaining 3 (5%) were due to pathologic myopia (2 cases) 
and POHS (1 case). Twelve eyes (19%) had recurrent SFCNV Clinical Ophthalmology 2008:2(4) 775
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after having previously received laser photocoagulation 
for extrafoveal or juxtafoveal CNV. The follow up interval 
following the ﬁ  rst PDT session ranged from 6 to 16 months 
(average 9 months) with 53% of the eyes followed for at 
least 9 months (equivalent of a maximum of 4 PDT sessions 
by TAP protocol). The number of treatment sessions over 
the period of follow-up ranged from 1 to 5 (average of 
2.7 sessions). The average pre-treatment GLD was 2585 μm 
(range: 400–4800 μm) and the average post-treatment GLD 
was 2103 μm (range: 0–6800 μm).
At the last follow up visit following PDT, 40 eyes (64%) 
had stable or decreased GLD of the lesion with no progression 
of leakage. Twenty-eight of 62 eyes (45%) had no evidence 
of CNV with absence of leakage (Figure 1). Twenty-two 
eyes (36%) had progression. Ten of these (45%) had at least 
doubling of the GLD of the neovascular lesion compared 
to pre-treatment. The latter could explain our observation 
that the average pre-treatment GLD (2585 μm) was not 
signiﬁ  cantly different from the average post-treatment GLD 
(2103 μm), although 64% of the eyes had stable or decreased 
GLD. Three study eyes (5%) developed a DS following 
PDT with an average scar size of 3200 ± 1345 μm 
(range: 2100–4700 μm) (Figure 2).
Fourteen patients (23%) had already had disciform 
scarring in their fellow eye at the time of presentation, 6 of 
these (43%) had previous laser therapy for CNV (Table 1). 
None of these eyes had previously received PDT. At last 
follow up visit, all but one of the 14 patients had a GLD of 
the neovascular lesion in the study eye smaller than the size 
of the scar in the fellow eye; and 7 of them (50%), had no 
evidence of CNV with absence of leakage in the study eye 
(Table 1). The average size of the DS in these 14 fellow eyes 
was 5900 ± 1866 μm (range: 2200–9200 μm). The average 
size of the DS that developed in eyes with previous laser 
therapy (6/14) was 5500 ± 2365 μm (range: 2200–9200 μm) 
and that in eyes without previous intervention (8/14; naturally 
occurring) was 6200 ± 1493 μm (range: 4000–8000 μm) 
(Figure 3; Table 2).
The average size of the DS that developed in 3 study eyes 
following PDT (3200 ± 1345 μm) was signiﬁ  cantly smaller 
than that of the fellow eyes of the subgroup of 14 patients 
(5900 ± 1866 μm), and than that of the 8 of 14 eyes without 
previous intervention (6200 ± 1493 μm) (Tables 2, 3). It was 
not signiﬁ  cantly smaller, however, than that of the 6 of 
14 eyes that had disciform scaring with prior laser treatment 
(5500 ± 2365 μm) (Tables 2, 3).
A
B
Figure 1 Pre-and post-treatment ﬂ  uorescein angiogram (FA) of the left eye of a 
patient with AMD-related predominantly classic SFCNV. A) Pre-treatment, late phase 
frame. B) Ten months after two sessions of PDT, late phase frame. Note absence of 
CNV leakage in the post-treatment angiogram.
Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovasculariza-
tion; PDT, photodynamic therapy; SFCNV, subfoveal choroidal neovascularization.
Figure 2 Disciform scar following PDT. Fundus picture of a patient with AMD-related 
SFCNV that evolved into a disciform scar following two sessions of PDT.   This was the 
largest scar that developed following treatment (GLD: 4700 μm).
Abbreviations: AMD, age-related macular degeneration; GLD, greatest linear dimension; 
PDT, photodynamic therapy; SFCNV, subfoveal choroidal neovascularization.Clinical Ophthalmology 2008:2(4) 776
Ghazi et al
The size of the DS that could have potentially developed 
following PDT was determined from the study eyes of the 
subgroup of 14 patients, and then also from the rest of the 
study eyes (45 eyes) excluding the 3 that developed DS. 
It was found to be 3607 ± 1389 μm and 3579 ± 1473 μm, 
respectively (Table 2). In either case, it was signiﬁ  cantly 
smaller than the average size of the scar in the fellow eyes 
of the subgroup of 14 patients (5900 ± 1866 μm), and of the 
8 of 14 without previous intervention (6200 ± 1493 μm) 
(Tables 2, 3). However, in both cases, it was not signiﬁ  cantly 
smaller than that of the 6 of 14 eyes that developed the 
scar following prior laser treatment (5500 ± 2365 μm) 
(Tables 2, 3).
Discussion
Photodynamic therapy is now one of the ﬁ  rst line treatment 
modalities used in the management of subfoveal CNV 
(VIP et al 2002). Its beneﬁ  t in reducing vision loss has been 
proven in the case of AMD-related predominantly classic 
SFCNV (TAP 1999; Bressler 2001), AMD-related occult 
SFCNV (VIP 2001b; Bressler 2002), and SFCNV related to 
pathologic myopia (VIP 2001a). Some evidence also exists 
for a treatment beneﬁ  t in other cases of SFCNV (Sickenberg 
et al 2000; Saperstein et al 2002; Busquets et al 2003). 
Although these clinical trials reported on the ﬂ  uorescein 
angiographic outcome following treatment and provided 
evidence that PDT could limit the size and progression of the 
CNV lesion, the main emphasis was on the reduction in the 
risk of moderate and severe visual loss associated with PDT. 
The effect of treatment on the size of the CNV lesion, 
particularly the evolution of the DS potentially associated 
with it, was less extensively assessed. Our study exclusively 
discusses this treatment beneﬁ  t of PDT regardless of the 
ﬁ  nal visual outcome, and supports the idea that the latter 
should not be the sole criterion by which treatment success 
is determined.
Over an average follow-up period of 9 months, we found 
that 64% of PDT treated eyes had stable or decreased GLD of 
the CNV lesion with no progression, 45% had no evidence of 
CNV with absence of leakage, and only 36% had progression 
at the last follow-up visit. These results compare favorably 
to those reported in the one-year follow up of the TAP trial 
(TAP 1999) where 19% of treated eyes had absence of 
leakage and 46% had progression. The explanation for this 
favorable outcome is two-fold. First, the majority of our study 
eyes had a lesion almost entirely composed of classic CNV 
(data not shown here). Although in a subgroup analysis in 
the TAP trial, lesion characteristics at baseline did not have 
a signiﬁ  cant effect on the magnitude of treatment beneﬁ  t 
on progression and ﬁ  nal lesion size more than 6 MPS disc 
areas, only three broad classes of lesions were analyzed: 
those with at least 50%, those with less than 50%, and 
those with no classic CNV. Those with at least 50% classic 
CNV were not further subdivided. Our group of study eyes 
constitutes one subgroup of those with at least 50% classic 
CNV and probably the one with the most favorable response 
to PDT as far as post-treatment lesion size and progression 
are concerned. Second, a selection bias, by virtue of the 
Table 1 Subgroup of 14 patients. GLD of the disciform scar in the fellow eyes and GLD of the neovascular lesion pre- and post-PDT 
in the study eyes
Case number GLD pre-PDT (micron) GLD post PDT (micron) Size of disciform scar 
























































13 2200 4300 2200
14 4800 4800 8000 Following laser
Abbreviations: GLD, greatest linear dimension; PDT, photodynamic therapy.Clinical Ophthalmology 2008:2(4) 777
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retrospective nature and inclusion criteria of the study, 
might be partially responsible. It is generally believed that 
patients with poor response to therapy are more likely to be 
noncompliant with treatment plans. Thus it is quite possible 
that the majority of eyes that had signiﬁ  cant progression and 
poor visual outcome early after treatment failed to maintain 
the desired follow-up criteria of this study with either a short 
(less than 6 months) or an irregular (did not adhere to the 
TAP protocol) follow-up, leading to subsequent exclusion. 
The result of that would be the inadvertent selection of eyes 
with better response to PDT.
The effect of PDT on lesion size and progression 
emphasized in this manuscript might be very signiﬁ  cant in 
determining the size of the DS and central scotoma that may 
ultimately develop in eyes with SFCNV. Disciform scarring 
is a frequent complication of neovascular maculopathy, 
particularly AMD (Green and Enger 1993). The evolution of 
a DS secondary to CNV has been described by Gass (1967a, 
1967b) who noted that repeated episodes of hemorrhage 
and exudation from these abnormal vessels in the subretinal 
and/or subpigment epithelial space result in retinal pigment 
epithelium (RPE) metaplasia with vascular and ﬁ  broblastic 
in-growth from the choroid. The end result is a disciform 
maculopathy. Subsequent studies supported this theory 
(Teeters and Bird 1973; Green and Key 1977). Based on 
this, an intervention that limits the activity (bleeding and 
exudation) of CNV would be expected to favorably alter 
the evolution of the DS. PDT has been shown to cause 
endothelial cell damage and denudation of the vascular 
basement membrane with subsequent platelet aggregation, 
thrombus formation and vascular occlusion (Ghazi et al 
2001). This effect, however, is short-lived because thrombus 
fragmentation and endothelial cell regeneration with 
re-population of the denuded basement membranes, result 
in re-perfusion of the occluded vessels following treatment 
(Ghazi et al 2001). This explains why repeated treatment 
sessions may be needed to maintain CNV non-perfusion. 
To understand the beneﬁ  cial effect of PDT on the evolution of 
the DS despite its short-lived effect, it is important to examine 
what happens to the CNV in between treatment sessions.
At the vascular level, during the period that the neovessels 
are occluded following each treatment session, and before 
reperfusion and leakage re-occur, mild exudation and 
hemorrhage, if at all, takes place. At the cellular level, after 
each treatment, newly regenerated endothelial cells replace 
the treated necrotic cells. Evidence for this phenomenon 
can be observed experimentally as early as the third day 
following PDT and is complete by 2 weeks (Royster et al 
1988). After the necrotic endothelial cells are regenerated, 
the following PDT session leads to their necrosis again, and 
the cycle continues with each treatment session. The newly 
regenerated, immature endothelial cells that replace the 
treated, mature cells might be less leaky. Evidence for this 
comes from previous ultrastructural studies which showed 
that development of endothelial fenestrations and loss of 
some of the surrounding pericytes are part of the maturation 
process of endothelial cells and capillaries lined by them 
(Ishibashi and Ryan 1992; Ishibashi et al 1995; Suzuki and 
Yoshida 1998). This may contribute to decreased exudation 
and hemorrhage in the early period following regeneration 
of treated capillaries and prior to their maturation. Therefore 
a logical implication would be that PDT could temporarily 
occlude active neovessels by virtue of thrombosis, and 
transform them into inactive vessels for at least a short period 
A
B
Figure 3 Disciform scars in 2 fellow eyes from the subgroup of 14 patients. A) Fundus 
picture of the largest scar that developed without previous intervention. B) Fundus 
picture of the largest scar that developed following previous laser treatment. This eye 
had received 2 sessions of laser photocoagulation for CNV.
Abbreviation: CNV, choroidal neovascularization.Clinical Ophthalmology 2008:2(4) 778
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following regeneration and reperfusion by virtue of capillary 
immaturity. Hence, less stimulus for RPE metaplasia and 
ﬁ  broblastic ingrowth as per Gass theory (Gass 1967a, 1967b), 
and a favorable inﬂ  uence on the evolution of the DS and 
central scotoma (Schmidt-Erfurth 1999).
The findings in our study support this hypothesis. 
The average size of the DS that developed in 3 study eyes 
following PDT (3200 ± 1345 μm) was signiﬁ  cantly smaller 
than the average size of the scar in the fellow eyes of the 
subgroup of 14 patients (5900 ± 1866 μm), and particularly 
the 8 of 14 without previous intervention (6200 ± 1493 μm) 
(Tables 2, 3). In addition, the average size of the potential DS 
derived from the study eyes of the subgroup of 14 patients 
(3607 ± 1389 μm) was signiﬁ  cantly smaller than that of the 
scar in their fellow eyes (5900 ± 1866 μm) (Tables 2, 3). 
One could argue that this comparison may be biased because 
patients with a DS and central scotoma in their fellow eye 
might seek care earlier due to the slightest disturbance of 
vision in their good eye secondary to increased awareness. 
To eliminate such bias, we also compared the average size 
of the DS in the fellow eyes of the subgroup of 14 patients 
(5900 ± 1866 μm) to that of the potential scar in the study 
eyes of the rest of the patients who do not have a DS in their 
fellow eye. The latter was found to be 3579 ± 1437 μm and 
was also signiﬁ  cantly smaller (Tables 2, 3). Therefore, the 
potential scar in both instances was signiﬁ  cantly smaller than 
the DS in the fellow eyes of the 14 patients. This was also true 
when comparison was made with the 8/14 fellow eyes that 
had a DS without previous intervention (6200 ± 1493 μm) 
(Tables 2, 3).
We also observed that there was no signiﬁ  cant difference 
between the average size of the scar in the 6/14 fellow eyes in 
which the scar developed following previous laser treatment 
(5500 ± 2365 μm) and that of the scar following PDT in the 
3 study eyes that developed scarring (3200 ± 1345 μm), the 
study eyes of the subgroup of 14 patients (3607 ± 1389 μm), 
or the study eyes of the rest of the patients (3579 ± 1473 μm), 
respectively (Tables 2, 3). So it also appears that laser 
treatment, like PDT, might have a beneﬁ  cial effect on the 
evolution of the DS. This, again, we believe is the result of 
the interruption of the active exudative phase of the CNV that 
leads to the development of disciform maculopathy.
One drawback of the subgroup analysis of our study is 
that the DS in the fellow eye of each of these 14 patients 
was already present at presentation. It was not prospectively 
observed to evolve; therefore, we could not tell with certainty 
whether the process started with SFCNV, or non-SFCNV 
with secondary subfoveal spread. Thus comparing disciform 
scars in these fellow eyes to actual and potential disciform 
scars secondary to documented SFCNV in the study eyes 
Table 2 Average size of disciform scars following PDT (actual and potential) and without PDT (with and without prior laser)
Disciform scar   
in fellow eye 
of  subgroup 
of 14 patients
Disciform 
scar in fellow 
eyes with no 
previous laser
Disciform scar in 
fellow eyes with 
previous  laser 
treatment
Disciform scar 
in study eyes 
following PDT
Potential scar 
post-PDT in study 
eyes of subgroup 
of 14 patients
Potential scar 
post-PDT in rest 
of study eyes 
excluding 3 eyes
Number of eyes 14 8 6 3 14 45
Average Size ± SD 
(micron)
5900 ± 1866 6200 ± 1493 5500 ± 2365 3200 ± 1345 3607 ± 1389 3579 ± 1473
Abbreviations: PDT, photodynamic therapy; SD, standard deviation.
Table 3 Comparison between the average size of the disciform scar following PDT (actual and potential) and that without PDT (with 
and without prior laser). Statistical analysis, p-value*
Disciform scar 
in 3 study eyes 
post-PDT
Potential disciform scar 
post-PDT in subgroup 
of 14 study eyes
Potential disciform scar 
post-PDT in rest of study 
eyes excluding 3 eyes
Disciform scar in subgroup of 
14 fellow eyes
0.044 0.002 0.0001
Disciform scar in 8 fellow eyes 
with no prior intervention
0.033 0.002 0.0004
Disciform scar in 6 fellow eyes 
following laser
0.108 0.139 0.068
Abbreviation: PDT, photodynamic therapy. 
Note: *Student t-test.Clinical Ophthalmology 2008:2(4) 779
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might be biased towards smaller scars in the study eyes. 
However, there is evidence that SFCNV is usually larger 
than non-SFCNV. Bressler and colleagues (1993) found that 
66% of CNV involving the subfoveal region were bigger 
than 1500 μm as opposed to 12% of CNV that did not. In 
addition, to our knowledge there is no evidence that the rate 
of CNV progression differs according to the location of the 
CNV. Therefore the subsequent scar is expected to be larger 
for SFCNV which is the location of CNV that all our study 
eyes had at presentation. Our results suggest that PDT may 
alter this expectation with a beneﬁ  cial effect on the evolution 
of the DS secondary to SFCNV. This appears to be related 
to the effect of PDT on the activity of the CNV as discussed 
above. Another drawback is that the DS that was already 
present in the fellow eye of these 14 patients at the time of 
initial examination might have developed over years. Thus, 
comparison with actual and potential disciform scars that 
developed or could have developed over the ﬁ  nite follow-up 
period of this study might be also biased. The best way to 
address this factor is by prospectively following a study group 
and a control group for a long period of time. However, the 
availability of treatment options such as PDT for SFCNV 
nowadays makes studies with a control group unfeasible. 
In addition, to our knowledge, these comparisons have not 
been performed in such prospective trials to date (TAP 1999; 
VIP 2001a, 2001b; Bressler 2001, 2002). A third drawback 
is that no measures of the central visual function other than 
visual acuity were performed on our patients. As has been 
demonstrated, central visual ﬁ  eld function and scotoma 
characteristics as demonstrated by microperimetry may yield 
valuable information regarding ﬁ  nal visual function and 
visual rehabilitation (Schmidt-Erfurth 2004).
This study shows evidence that the DS and potentially 
the subsequent central scotoma that might develop following 
PDT is expected to be smaller than that which develops 
naturally secondary to predominantly classic SFCNV. In 
microperimetric analysis studies of the central scotoma, 
PDT was associated with an improvement in the central 
visual ﬁ  eld and reduction in scotoma size and intensity 
(Schmidt-Erfurth 1999, 2004). This might prove to be a 
very signiﬁ  cant effect of PDT in neovascular maculopathy 
particularly in patients who fail the beneﬁ  t of PDT in 
preventing visual loss. The literature has accumulating 
evidence that visual rehabilitation of patients with a smaller 
DS and central scotoma might be easier and more rewarding 
(Timberlake et al 1986, 1987; Whittaker et al 1988; Fletcher 
and Schuchard 1997; Schuchard and Fletcher 2000). This 
is because the size of the central scotoma is thought to be 
the most important factor in determining both the functional 
characteristics of the preferred retinal locus/loci (PRL(s)) 
that these patients develop for ﬁ  xation, and the anatomic 
proximity of that locus/loci to the fovea (von Noorden and 
Mackensen 1962; Sunness et al 1996). Both factors may 
be signiﬁ  cantly important in rehabilitating patients who 
lost central vision (von Noorden and Mackensen 1962; 
Fletcher and Schuchard 1997; Schuchard and Fletcher 
2000). In recent studies, reading speed, macular sensitivity, 
macular electrophysiology, and ﬁ  xation patterns correlated 
with the extent of macular impairment in choroidal 
neovascularization and appeared to improve following PDT 
(Ergun et al 2003; Midena et al 2004; Varano et al 2005; 
Yodoi et al 2007).
Ophthalmologists and researchers should not overlook 
the beneﬁ  t of PDT emphasized in this paper. This important 
beneﬁ  t has been probably underestimated and overshadowed 
because of the emphasis that ophthalmologists invest 
in the direction of ﬁ  nal visual acuity outcome following 
treatment. Long-follow-up, controlled prospective studies 
with emphasis on the size of the DS and central scotoma, 
with utilization of microperimetry with scanning laser 
ophthalmoscopy could demonstrate the value of PDT in 
limiting the size of the eventual DS and central scotoma 
in patients with predominantly classic SFCNV. Also they 
could possibly determine any beneﬁ  cial effect of PDT in 
the rehabilitation process of treated patients. However, 
prospectively following a control group with SFCNV might 
not be feasible nowadays due to the availability of treatment 
options such as PDT. Re-evaluating patients enrolled in 
previous clinical trials (TAP 1999; VIP 2001a, 2001b; 
Bressler 2001, 2002) is one potential way for testing our 
hypothesis.
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